Tag: Jacques-François Martin
Company News: Anergis Closes Series B Financing Round Totaling CHF 14.5 Million
– Two U.S.-based family offices join as new investors
– All Series A investors participate in the round
Anergis, a company developing proprietary ultra-fast allergy vaccines, today announced the closing of a Series B financing round totaling CHF 14.5 million (€ 12.1 million, US$ 15 million). All Series A investors participated in the round together with new private European and U.S.-based investors. The financing was jointly led by existing investors Sunstone Capital, BioMedInvest and Renaissance PME as well as new investor WJFS, Inc. Anergis has so far raised a total of CHF 44 million in private equity, which includes the latest Series B financing round.
The funds will be used to advance Anergis´ birch allergy vaccine AllerT closer to market. The company is currently preparing the Phase III clinical trial program of AllerT. Anergis has already demonstrated the rapid and long-lasting clinical efficacy of AllerT in two subsequent field-based clinical Phase II trials. The funds will also be used to advance the AllerR ragweed allergy program towards clinical testing, as well as to research and discover undisclosed new Contiguous Overlapping Peptide (COP) allergy vaccines.
Company News: Anergis Appoints Dr. Dino Dina to its Board of Directors
– Company appoints seasoned US vaccine and biotech executive –
Anergis, a company focusing on proprietary allergy vaccines, today announced the appointment of Dino Dina, MD, to its Board of Directors. Dr. Dina brings extensive expertise in the research and development of vaccines for allergy, cancer and infectious diseases as well as in building successful US biopharmaceutical companies.
From 1998 to 2013, Dr. Dina served as Chief Executive Officer of Dynavax Technologies Corporation and has been a member of Dynavax´ Board of Directors since 1997. During his tenure, he secured extensive financing through corporate alliances (UCB, Sanofi, AstraZeneca, GSK, Merck), private financings, an initial public offering (2004), and a series of public equity financings. Prior to joining Dynavax, Dr. Dina held a series of positions with increasing responsibility at Chiron Corporation, where he ultimately served as President of Chiron Vaccines. Under Dr. Dina’s direction, Chiron Vaccines received the first-ever approval of an adjuvanted influenza vaccine in Italy, successfully completed development of the first genetically engineered pertussis vaccine, and conducted clinical trials for vaccines to prevent HIV, herpes simplex type II, cytomegalovirus, and hepatitis B infections.
Company News: Anergis Appoints Jacques-François Martin as Chairman of the Board of Directors
Anergis, a clinical-stage biopharmaceutical company developing novel allergy vaccines, today announced the appointment of Jacques-François Martin, Chairman and CEO of vaccine company Mymetics, as Chairman of the Board of Directors.
Anergis develops allergy vaccines based on its proprietary technology of “Contiguous Overlapping Peptides” (“COPs”). Anergis’ lead allergy vaccine, called “AllerT”, is in clinical Phase IIb development and is designed to provide ultra-fast and safe desensitization to birch pollen allergy, a widespread condition in developed countries. Anergis’ vaccines are designed to provide long-term protection against allergies with a 2-month treatment.
Jacques-François Martin is Chairman and CEO of Mymetics Corporation. Previously, he was CEO of Chiron Vaccines (now Novartis) from 1991 to 1993 and CEO of Pasteur-Mérieux (now Sanofi-Pasteur) from 1988 to 1991. In addition, he held leadership positions with not‐for‐profit organizations dedicated to the development of vaccines for debilitating and life-threatening diseases in both developed nations and third world countries. Among others, he was the first President and CEO of The Vaccine Fund (Bill and Melinda Gates Foundation) from 2000 to January 2005 and a member of the Board of the International AIDS Vaccine Initiative (IAVI) from November 1997 to June 2003. He started his executive career as Chief Executive Officer of Rhône-Poulenc Pharma in Hamburg, Germany, in 1970. Mr. Martin is a member of the French Academy of Technologies and an officer in the French Order of Merit.